Cargando…

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

AQ4 (1,4-Bis-{[2-(dimethylamino-N-oxide)ethyl]amino}5,8-dihydroxyanthracene-9, 10-dione) is a prodrug designed to be excluded from cell nuclei until bioreduced in hypoxic cells to AQ4, a DNA intercalator and topoisomerase II poison. Thus, AQ4N is a highly selective bioreductive drug that is activate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patterson, L H, McKeown, S R, Ruparelia, K, Double, J A, Bibby, M C, Cole, S, Stratford, I J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363261/ https://www.ncbi.nlm.nih.gov/pubmed/10864207 http://dx.doi.org/10.1054/bjoc.2000.1163

Ejemplares similares

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2001)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2002)

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
por: Hejmadi, M. V., et al.
Publicado: (1996)

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
por: McKeown, S. R., et al.
Publicado: (1995)

Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
por: Butler, S. A., et al.
Publicado: (1997)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

AQ4N: a new approach to hypoxia-activated cancer chemotherapy
por: Patterson, L H, et al.
Publicado: (2000)

Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
por: Bibby, M. C., et al.
Publicado: (1981)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours.
por: Bibby, M. C., et al.
Publicado: (1991)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation
por: Janssens, M Y, et al.
Publicado: (1999)

Pretreatment apoptosis in carcinoma of the cervix correlates with changes in tumour oxygenation during radiotherapy
por: Sheridan, M T, et al.
Publicado: (2000)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
por: Doherty, G. P., et al.
Publicado: (1998)

Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311
por: Burger, A M, et al.
Publicado: (1999)

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
por: Walter, W, et al.
Publicado: (2000)

Effects of agents which inhibit the regulation of intracellular pH on murine solid tumours.
por: Newell, K., et al.
Publicado: (1992)

The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide.
por: Bibby, M. C., et al.
Publicado: (1988)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

Enhancement of chemotherapy by manipulation of tumour pH
por: Raghunand, N, et al.
Publicado: (1999)

Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.
por: Double, J. A., et al.
Publicado: (1986)

Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: independence from tumour radiosensitivity
por: Cooper, R A, et al.
Publicado: (1999)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.
por: Olive, P. L.
Publicado: (1995)

Chemotherapy for unresectable and recurrent intramedullary glial tumours in children
por: Doireau, V, et al.
Publicado: (1999)

Unique chemosensitivity of MAC 16 tumours to flavone acetic acid (LM975, NSC 347512).
por: Bibby, M. C., et al.
Publicado: (1988)

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy
por: Korbelik, M, et al.
Publicado: (2000)

Case of Poisoning by Aq. Ammonia
por: Patterson, A.
Publicado: (1857)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
por: Hodgkiss, R. J., et al.
Publicado: (1995)

The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion.
por: Parkins, C. S., et al.
Publicado: (1997)

Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
por: Bremner, J. C., et al.
Publicado: (1992)

The Sensitivity to Chemotherapeutic Agents of a Rat Tumour Grown in Immunosuppressed Mice
por: Sheard, Christine E., et al.
Publicado: (1971)

Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
por: Bibby, M. C., et al.
Publicado: (1991)

Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.
por: Bailey, S. M., et al.
Publicado: (1997)

The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours
por: Cook, A M, et al.
Publicado: (2001)

Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia‐activated prodrugs (uHAPs)
por: Smith, Paul J., et al.
Publicado: (2022)

The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease
por: Pidgeon, G P, et al.
Publicado: (1999)

Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent
por: Seker, H, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_iv157h2o3bp4ri9tkmvls0e3tn